PSFG
ALNY icon

Park Square Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Park Square Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-121
Closed -$28.5K – 966
2024
Q4 		$28.5K Buy
+121
New +$31.8K 0.02% 360

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Park Square Financial Group's ALNY Position: Q1 2025 in Review

Park Square Financial Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 121 shares — an estimated $28.5K sold.

Park Square Financial Group first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $28.5K in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Park Square Financial Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Park Square Financial Group sold 121 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $28.5K.
  • Park Square Financial Group first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Park Square Financial Group's Alnylam Pharmaceuticals position peaked at $28.5K in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Park Square Financial Group's 13F filing for Q1 2025, filed 1 May 2025.